LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

0.53 1.92

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.51

Max

0.54

Põhinäitajad

By Trading Economics

Sissetulek

31M

-34M

Müük

25M

27M

Aktsiakasum

-0.09

Kasumimarginaal

-127.16

Töötajad

103

EBITDA

30M

-30M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+592.45% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

139M

245M

Eelmine avamishind

-1.39

Eelmine sulgemishind

0.53

Uudiste sentiment

By Acuity

53%

47%

317 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. nov 2024, 12:42 UTC

Suurimad hinnamuutused turgudel

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

592.45% tõus

12 kuu keskmine prognoos

Keskmine 3.67 USD  592.45%

Kõrge 6 USD

Madal 1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

317 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.